Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Flexible regression models for ROC and risk analysis, with or without a gold standard.

Branscum AJ, Johnson WO, Hanson TE, Baron AT.

Stat Med. 2015 Dec 30;34(30):3997-4015. doi: 10.1002/sim.6610. Epub 2015 Aug 3.

2.

Ovarian cyst fluids are a cache of tumor biomarkers that include calgranulin A and calgranulin B isoforms.

Skaggs HS, Saunders BA, Miller RW, Goodrich ST, King MS, Kimbler KD, Branscum AJ, Fung ET, DePriest PD, van Nagell JR, Ueland FR, Baron AT.

Cancer Invest. 2013 Aug;31(7):433-53. doi: 10.3109/07357907.2013.802799.

PMID:
23915068
3.

Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab.

Wilken JA, Perez-Torres M, Nieves-Alicea R, Cora EM, Christensen TA, Baron AT, Maihle NJ.

Biochemistry. 2013 Jul 2;52(26):4531-40. doi: 10.1021/bi400437d. Epub 2013 Jun 21.

PMID:
23731208
4.

Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer.

Podzielinski I, Saunders BA, Kimbler KD, Branscum AJ, Fung ET, DePriest PD, van Nagell JR, Ueland FR, Baron AT.

Cancer Invest. 2013 May;31(4):258-72. doi: 10.3109/07357907.2013.789896.

PMID:
23627408
5.

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ.

Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.

6.

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Cosentino-Boehm AL, Lafky JM, Greenwood TM, Kimbler KD, Buenafe MC, Wang Y, Branscum AJ, Yang P, Maihle NJ, Baron AT.

Diagnostics (Basel). 2013 Jan 14;3(1):13-32. doi: 10.3390/diagnostics3010013.

7.

Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment.

Ma W, Ma J, Xu J, Qiao C, Branscum A, Cardenas A, Baron AT, Schwartz P, Maihle NJ, Huang Y.

Cell Cycle. 2013 Jan 1;12(1):88-97. doi: 10.4161/cc.23028. Epub 2012 Dec 19.

8.

EGFR/HER-targeted therapeutics in ovarian cancer.

Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ.

Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Review.

9.

The epidermal growth factor receptor conundrum.

Wilken JA, Baron AT, Maihle NJ.

Cancer. 2011 Jun 1;117(11):2358-60. doi: 10.1002/cncr.25805. Epub 2010 Dec 14. No abstract available.

10.

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin.

Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ.

Biochemistry. 2011 May 24;50(20):4309-21. doi: 10.1021/bi200126j. Epub 2011 Apr 27.

11.

Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ.

Cancer Treat Res. 2009;149:189-202. doi: 10.1007/978-0-387-98094-2_9. Review. No abstract available.

PMID:
19763437
12.

Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.

Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ.

IDrugs. 2009 May;12(5):302-8. Review.

PMID:
19431095
13.

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ.

Cancer Res. 2009 Mar 15;69(6):2191-4. doi: 10.1158/0008-5472.CAN-08-1056. Epub 2009 Mar 10.

14.

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

Lafky JM, Wilken JA, Baron AT, Maihle NJ.

Biochim Biophys Acta. 2008 Apr;1785(2):232-65. doi: 10.1016/j.bbcan.2008.01.001. Epub 2008 Feb 7. Review.

PMID:
18291115
15.

Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.

Martin FM, Harris AM, Rowland RG, Conner W, Lane M, Durbin E, Baron AT, Kyprianou N.

Gene Ther Mol Biol. 2008;12(2):253-258.

16.

Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.

Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT, Kyprianou N.

J Urol. 2007 Nov;178(5):2176-80. Epub 2007 Sep 17.

17.

Soluble epidermal growth factor receptor acridinium-linked immunosorbent assay.

Lafky JM, Baron AT, Maihle NJ.

Methods Mol Biol. 2006;327:39-47.

PMID:
16780211
18.

Nadir CA125 concentration as a prognostic indicator in ovarian cancer.

Baron AT, Maihle N.

Nat Clin Pract Oncol. 2005 Jun;2(6):288-9. No abstract available.

PMID:
16264982
19.

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.

Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ.

Cancer Res. 2005 Apr 15;65(8):3059-62.

20.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

21.

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.

22.

A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.

Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN.

Ann Oncol. 2002 Aug;13(8):1225-35.

PMID:
12181246
23.

Generation and characterization of polyclonal antibodies specific for human p110 sEGFR.

Christensen TA, Reiter JL, Baron AT, Maihle NJ.

Hybrid Hybridomics. 2002 Jun;21(3):183-9.

PMID:
12165144
24.

EGF/ErbB receptor family in ovarian cancer.

Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC.

Cancer Treat Res. 2002;107:247-58. Review.

PMID:
11775453
25.

A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.

Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1175-85.

26.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

27.

A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.

Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ.

J Immunol Methods. 1998 Oct 1;219(1-2):23-43.

PMID:
9831386
28.

Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain.

Baron AT, Huntley BK, Lafky JM, Reiter JL, Liebenow J, McCormick DJ, Ziesmer SC, Roche PC, Maihle NJ.

Hybridoma. 1997 Jun;16(3):259-71.

PMID:
9219036
29.

Centrin-based contractile fibers: chromatographic purification of centrin.

Baron AT, Errabolu R, Dinusson J, Salisbury JL.

Methods Cell Biol. 1995;47:341-51. No abstract available.

PMID:
7476509
30.

The pericentriolar lattice of PtK2 cells exhibits temperature and calcium-modulated behavior.

Baron AT, Suman VJ, Nemeth E, Salisbury JL.

J Cell Sci. 1994 Nov;107 ( Pt 11):2993-3003.

31.

Centrin is a component of the pericentriolar lattice.

Baron AT, Greenwood TM, Bazinet CW, Salisbury JL.

Biol Cell. 1992;76(3):383-8.

PMID:
1305481
32.

Localization of the centrin-related 165,000-Mr protein of PtK2 cells during the cell cycle.

Baron AT, Greenwood TM, Salisbury JL.

Cell Motil Cytoskeleton. 1991;18(1):1-14.

PMID:
2004430
33.
34.
35.

Membrane IgM: interactions with the cortical cytoskeleton in the human lymphoblastoid cell line WiL2.

Salisbury JL, Baron AT, Keller GA, Skiest D.

Cell Motil Cytoskeleton. 1988;9(2):140-52.

PMID:
3162834
36.

Calcium-modulated contractile proteins associated with the eucaryotic centrosome.

Salisbury JL, Baron AT, Coling DE, Martindale VE, Sanders MA.

Cell Motil Cytoskeleton. 1986;6(2):193-7.

PMID:
3518957

Supplemental Content

Loading ...
Support Center